What is Zacks Research's Forecast for ResMed Q2 Earnings?

ResMed Inc. (NYSE:RMD - Free Report) - Stock analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for ResMed in a research note issued on Tuesday, November 12th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.24 per share for the quarter, up from their previous forecast of $2.19. The consensus estimate for ResMed's current full-year earnings is $9.22 per share. Zacks Research also issued estimates for ResMed's Q3 2025 earnings at $2.27 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $9.06 EPS, Q2 2026 earnings at $2.32 EPS, Q3 2026 earnings at $2.47 EPS, Q4 2026 earnings at $2.48 EPS, FY2026 earnings at $9.52 EPS and FY2027 earnings at $10.46 EPS.

A number of other analysts also recently commented on the company. KeyCorp upped their target price on ResMed from $251.00 to $266.00 and gave the stock an "overweight" rating in a research note on Friday, October 25th. Robert W. Baird raised their price objective on shares of ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. Royal Bank of Canada boosted their target price on shares of ResMed from $224.00 to $232.00 and gave the company a "sector perform" rating in a research note on Friday, October 25th. Wolfe Research reaffirmed an "underperform" rating and issued a $180.00 price target on shares of ResMed in a report on Wednesday, September 18th. Finally, Bank of America increased their target price on ResMed from $240.00 to $270.00 and gave the company a "buy" rating in a research report on Thursday, September 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ResMed currently has an average rating of "Moderate Buy" and a consensus price target of $225.70.

ResMed Stock Performance

NYSE RMD traded down $4.01 on Thursday, reaching $231.43. 1,084,398 shares of the company's stock traded hands, compared to its average volume of 1,048,772. The stock has a 50 day moving average price of $243.30 and a 200-day moving average price of $223.37. The firm has a market cap of $33.97 billion, a price-to-earnings ratio of 30.65, a P/E/G ratio of 1.81 and a beta of 0.69. ResMed has a fifty-two week low of $147.31 and a fifty-two week high of $260.49. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.17. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The firm's revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.64 EPS.

Institutional Trading of ResMed

A number of hedge funds have recently added to or reduced their stakes in the stock. OFI Invest Asset Management acquired a new position in shares of ResMed during the 2nd quarter worth $32,000. Ashton Thomas Securities LLC acquired a new position in ResMed during the third quarter worth about $34,000. Versant Capital Management Inc grew its position in shares of ResMed by 196.7% in the second quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 120 shares during the last quarter. Financial Connections Group Inc. purchased a new position in shares of ResMed during the 2nd quarter worth approximately $37,000. Finally, Blue Trust Inc. raised its position in shares of ResMed by 182.7% during the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 137 shares during the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Kaushik Ghoshal sold 5,000 shares of ResMed stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the sale, the insider now owns 21,788 shares of the company's stock, valued at approximately $5,502,777.28. The trade was a 18.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Michael J. Rider sold 882 shares of ResMed stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $231.00, for a total transaction of $203,742.00. Following the completion of the transaction, the general counsel now owns 10,512 shares of the company's stock, valued at $2,428,272. This trade represents a 7.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,056 shares of company stock valued at $15,086,020 in the last ninety days. 0.71% of the stock is currently owned by corporate insiders.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be issued a $0.53 dividend. The ex-dividend date is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a yield of 0.92%. ResMed's payout ratio is 28.08%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.